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REDUCING STRAY RADIATION DOSE FOR A PEDIATRIC PATIENT
RECEIVING PROTON CRANIOSPINAL IRRADIATION
Phillip J. Taddei, Dragan Mirkovic, Jonas D. Fontenot, Annelise Giebeler, Yuanshui Zheng,
Uwe Titt, Shiao Woo, and Wayne D. Newhauser*
The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 94,
Houston, Texas 77030

Abstract
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The aim of this study was to quantify stray radiation dose from neutrons emanating from a proton
treatment unit and to evaluate methods of reducing this dose for a pediatric patient undergoing
craniospinal irradiation. The organ equivalent doses and effective dose from stray radiation were
estimated for a 30.6-Gy treatment using Monte Carlo simulations of a passive scattering treatment
unit and a patient-specific voxelized anatomy. The treatment plan was based on computed
tomography images of a 10-yr-old male patient. The contribution to stray radiation was evaluated
for the standard nozzle and for the same nozzle but with modest modifications to suppress stray
radiation. The modifications included enhancing the local shielding between the patient and the
primary external neutron source and increasing the distance between them. The effective dose from
stray radiation emanating from the standard nozzle was 322 mSv; enhancements to the nozzle reduced
the effective dose by as much as 43%. These results add to the body of evidence that modest
enhancements to the treatment unit can reduce substantially the effective dose from stray radiation.
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I. INTRODUCTION
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Proton therapy is an effective treatment modality for central nervous system tumors in pediatric
patients. Proton beams have a finite range, which virtually eliminates the exit dose. This gives
proton therapy a dosimetric advantage over photon radiotherapy in the sparing of nearby tissues
and organs. Normal tissue sparing is paramount for children, who generally have longer
expected survival times and are more sensitive to radiation. Furthermore, young children have
smaller bodies than adults, and consequently, healthy organs are closer to the therapeutic
radiation field. These factors increase the patient’s lifetime risk of radiation carcinogenesis.
The therapeutic proton dose distribution within the patient has been thoroughly examined;
exposures from stray radiation are poorly understood and controversial. Absorbed dose from
stray neutrons is of particular concern because the relative biological effectiveness of neutrons
for carcinogenesis is higher than that of photons. Stray neutrons are produced in both the
treatment unit (or “external neutrons”) and inside the patient (or “internal neutrons”).1 The
patient’s exposure to external neutrons depends on the design of the proton treatment unit and
the treatment technique.2 For passively scattered proton therapy (PSPT), the final, field-
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defining collimator is a predominant source of external neutrons.3,4 Recently, Newhauser et
al. estimated an effective dose from external neutrons of 98 mSv in an adult male patient who
underwent a 36-Gy craniospinal irradiation (CSI) using PSPT (Ref. 5), and Taddei et al.
estimated an effective dose from external neutrons of 344 mSv for a 10-yr-old boy who
underwent a 30.6-Gy CSI with a 23.4-Gy boost PSPT treatment, both with PSPT, which
corresponded to a 2.8% lifetime risk of second cancer mortality.6 The results from these studies
suggest that it is important to refine calculations of stray radiation doses and to find ways to
reduce them.
Strategies were recently examined for reducing the effective dose from stray radiation for an
adult patient undergoing PSPT for prostate cancer.7 Modest modifications to the treatment unit
(i.e., adding a proton collimator far upstream of the patient, changing the composition of the
field-defining collimator from brass to tungsten alloy, and increasing the local shielding near
the patient) reduced the effective dose from stray radiation emanating from the treatment unit
from 320 to 108 mSv. These methods may also be effective for improving proton CSI, which
is technologically more demanding than proton radiotherapy of the prostate.
The aim of this study was to evaluate two strategies to reduce stray radiation exposures for a
pediatric patient undergoing CSI delivered using a PSPT unit:
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1.

modifying the field-defining collimator

2.

adding an extra upstream collimator.

Monte Carlo simulations were performed to evaluate the performance of these modifications.

II. METHODS
II.A. Monte Carlo Model
In this study a proton radiotherapy treatment was simulated for a 10-yr-old male patient with
a supratentorial primitive neuroectodermal tumor who underwent proton CSI using a PSPT
treatment unit (PROBEAT; Hitachi America, Ltd., Tarrytown, New York) at our institution.
The plan was created using a commercial treatment planning system (Eclipse Proton Planning;
Varian Medical Systems, Inc., Palo Alto, California)8 and wholebody kilovoltage computed
tomography (CT) images. The treatment fields, patient, and nozzle specifications are described
elsewhere6 and are summarized here for the readers’ convenience.
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For the complete treatment plan, the prescribed dose to 100% of the volumes of the brain and
spinal cord was 30.6 Gy, and the prescribed dose to the boost clinical target volume (a
subvolume of the brain) was an additional 23.4 Gy. The boost field for this patient contributed
only 5% to the effective dose from stray radiation and, for simplicity, was not considered in
the present analysis. Therefore, the simulated treatment included four CSI fields: an inferior
posterior-anterior (IPA) spinal field, a superior posterior-anterior (SPA) spinal field, a right
posterior oblique (RPO) cranial field, and a left posterior oblique (LPO) cranial field. The
spinal and cranial fields had proton beam energies of 140 and 180 MeV at the entrance of the
treatment head, penetration ranges in the patient of approximately 9- and 10-cm water
equivalent thickness, spread-out Bragg peak widths of 7 and 16 cm, and nominal air gaps of
10 and 2 cm between the distal component of the treatment unit and the proximal surface of
the patient, respectively. Beam modifiers included a range-modulator wheel, scattering foil,
range shifter, collimator block, and range compensator.8 The largest of the three available
snouts was used for all treatment fields (field size up to 25 × 25 cm2). The thickness of the
field-defining collimator was 4 cm for the spinal beams and 6 cm for the cranial beams.
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The Monte Carlo simulations were performed using the Monte Carlo N-Particle eXtended
(MCNPX) code (version 2.6b) (Ref. 9) with parallel computing methods. The MCNPX model
of the treatment unit included a realistic proton source, the beam-modifying devices, the
structural and housing components, and various static collimators.8,10 A voxelized phantom
represented the patient and was based on CT images for the 10-yr-old male patient, which
included the entire body except the feet. The Hounsfield unit, or CT number, in each pixel was
converted to a mass density and a biological material composition in the corresponding voxel.
11 Material compositions, variance-reduction information, selected physics options, and other
model specifications were provided in detail elsewhere6 and are available from the authors
upon request.
II.B. Treatment Unit Modifications
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In the first modification, the thickness of the field-defining collimator was increased from 4 to
8 cm for the spinal fields and from 6 to 8 cm for the cranial fields. Additionally, the composition
of each field-defining collimator was changed from brass (density = 8.38 g cm−3) to tungsten
(density = 19.29 g cm−3). This increased the shielding in the nozzle. In the second modification,
a pair of jaws made of tungsten alloy were introduced inside the nozzle 186 cm upstream from
the isocenter. The orthogonal jaws collimated the proton field to a rectangular shape. The lateral
dimensions of the jaws were based on the maximum and minimum lateral extents of the fielddefining collimator, reduced (i.e., demagnified) to take into account the proximity to the virtual
source at 270 cm from the isocenter and expanded by 20% to minimize the edge-scatter
effects12 on the dose distribution of the therapeutic beam.
II.C. Dosimetric Calculations
The effective dose from external neutrons E was calculated as

(1)

where
wT = weighting factor for each organ or tissue T
HT = organ equivalent dose from stray radiation.13
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The wT values were taken from the International Commission on Radiological Protection
(ICRP) Publication 60 (Ref. 14). HT was calculated for external neutrons for each field as the
product of the radiation weighting factor wR and the mean absorbed dose for each organ or
tissue DT or
(2)

The wR values were calculated using the neutron spectral fluence incident upon the voxelized
phantom according to the relationship between wR and neutron energy given in ICRP
Publication 92 (Ref. 13). Because wR varied only slightly (<4%) for similar nozzle
configurations,6 for simplicity a mean value of wR was estimated for each beam of the standard
nozzle and applied to the modified nozzles. DT was the mass-weighted average of the absorbed
dose of all voxels within the organ or tissue. An exception was made for the skin and remainder
organs and tissues, for which, for each field, DT was approximated as the average absorbed
dose for all voxels within the phantom. Although the effective dose from internal neutrons was
calculated in a previous work,6 in this study internal neutrons were not considered because
their intensity could not be reduced by improvements to the nozzle.

Nucl Technol. Author manuscript; available in PMC 2010 September 21.

Taddei et al.

Page 4

NIH-PA Author Manuscript

In separate simulations for therapeutic protons and external neutrons, the absorbed dose in each
voxel per source particle Dν/sp (in Gy sp−1) was computed. For the external neutron
simulations, all proton trajectories were terminated immediately upstream of the patient by a
proton-stopping plane (imp:h = 0). For the therapeutic proton simulations (mode n h; imp:h >
0; imp:n = 0), the mass-averaged absorbed dose per source particle in the target volume
DT=target/sp was calculated for each treatment beam. This value was then used to normalize
Dν/sp from external neutrons separately for each nozzle configuration and each treatment field,
resulting in E (in mSv Gy−1), HT (in mSv Gy−1), and DT (in mGy Gy−1). The E and HT values
from individual treatment fields were combined to yield the corresponding quantities for the
entire course of 30.6 Gy. The methods for calculating these quantities are described in detail
elsewhere.6,7
External neutron simulations were performed using the following nozzle configurations: the
standard nozzle, the standard nozzle with the modified field-defining collimator, the standard
nozzle with the additional jaws, and the standard nozzle with both the modified collimator and
the additional jaws. Therapeutic proton simulations were performed for the standard nozzle
and for the standard nozzle with the jaws; a comparison confirmed that the therapeutic dose
was not perturbed by the nozzle modifications.
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To achieve acceptable statistical uncertainties in DT, 1 × 109 and 5 × 108 source particle
histories were tracked for the spinal field and cranial field simulations, respectively. Geometry
splitting at the surface of the voxelized phantom reduced the variance in the values of Dν.
Statistical uncertainties were based on the coefficients of variation reported by the MCNPX
code. The uncertainties in the mean wR values were disregarded because the variance was
minimal; the uncertainties in the wT values were assumed to be zero because these values were
set by definition rather than measurement. Statistical uncertainties were reported at the 68%
confidence interval.

III. RESULTS
The values of effective dose from external neutrons E for each nozzle configuration are listed
in Table I. As shown, E for the standard nozzle was 322.0 ± 0.6 mSv. E was reduced by 104.9
± 0.8 mSv (33%) by changing the field-defining collimator material, 58.2 mSv ± 0.8 (18%) by
adding jaws, and 138.7 ± 0.8 mSv (43%) by making both modifications.
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Table II summarizes the exposure to external neutrons for the standard nozzle and the nozzle
with modified collimator and jaws. The results are broken down by organ and by treatment
field. Reductions in HT ranged from 33 to 59% for the spinal fields and from 10 to 26% for
the cranial fields. The modifications reduced E by 51% (from 236.5 to 115.6 mSv) for the
spinal fields and by 21% (from 171.0 to 135.4 mSv) for the cranial fields.
The total computing time for all simulations was 15.3 cpu·years using parallel processing on
2.6-GHz, 64-bit processors (AMD Opteron; Advanced Micro Devices, Inc., Sunnyvale,
California).

IV. DISCUSSION
This study has demonstrated that improved shielding of a proton treatment unit can
substantially reduce the effective dose from stray radiation emanating from the treatment
apparatus. The clinical implication is that the reduction in the effective dose will reduce the
lifetime risk of radiation carcinogenesis. For the standard nozzle, the effective dose from
external neutrons E was 322 mSv. By replacing the 4- or 6-cm brass field-defining collimator
with an 8-cm tungsten field-defining collimator, E was reduced by 33%. By adding a pair of
jaws made of tungsten-alloy far upstream of the patient, E was reduced by 18%. By making
Nucl Technol. Author manuscript; available in PMC 2010 September 21.
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both modifications, E was reduced by 43%, and percentage reductions in the organ equivalent
dose from external neutrons HT ranged from 33 to 59% for the spinal fields and from 10 to
26% for the cranial fields. The increased performance of the modifications for the spinal fields
versus that of the cranial fields may be attributed to several variables, including the proton
beam energy, field size, field shape, and proximity of radiosensitive organs (see also Ref. 2).
This finding is similar to previous results for reducing E for PSPT for prostate cancer. Taddei
et al.7 reported that modest modifications to a PSPT treatment unit reduced by 66% the effective
dose from stray radiation originating in the nozzle. Thus, this study shows that for a second
treatment site, the stray radiation emanating from a PSPT treatment unit was reduced
substantially by making modest modifications to the treatment unit, approaching what may be
achieved through alternative nozzle designs (e.g., an ideal nozzle that implements a spotscanning technique).
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In a previous study,6 the contribution of internal neutrons to effective dose was estimated to
be 74 mSv for all four CSI treatment fields. Therefore, the effective dose from both internal
and external stray radiation was 396 mSv for the standard nozzle and 257 mSv for the nozzle
with a tungsten field-defining collimator and additional jaws. The National Council on
Radiation Protection and Measurements (NCRP) has recommended a risk coefficient of 8.1%/
Sv of effective dose for low-dose-rate, exposure-induced death for males between the ages of
0 to 19 yr (Ref. 15). The corresponding predicted excess attributable lifetime risk of second
cancer fatality for the boy in this study was 3.2% for the standard nozzle and 2.1% for the
nozzle with both modifications. That is, the modifications may result in about 11 fewer deaths
from stray radiation per 1000 male pediatric patients treated in this way. For pediatric females,
the same reduction in effective dose would correspond to about 16 fewer deaths per 1000
treated. However, the recommendations of the NCRP were based on data from a healthy
population. The relative biological effectiveness of neutrons for radiogenic cancer mortality
may be higher for a cancer population than for the general population. Therefore, the true risk
(and risk reduction) for pediatric patients undergoing proton CSI may be even larger, which
underscores the importance of improving proton beam delivery techniques to reduce patient
exposures to stray radiation.
In conclusion, using Monte Carlo simulations, we found that it is possible to reduce the effective
dose from stray radiation emanating from a PSPT treatment unit for a pediatric patient
undergoing proton CSI by 43%.
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TABLE I

NIH-PA Author Manuscript

Effective Dose from External Neutrons E and Standard Deviation in E, σE, for the Standard Nozzle and Modified
Nozzles
Nozzle

E
(mSv)

σE
(mSv)

Standard

322.0

0.6

Modified collimator

217.1

0.5

Additional jaws

263.7

0.6

Modified collimator and jaws

183.2

0.5
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0.20
0.12
0.12
0.12
0.12
0.05
0.05
0.05
0.05
0.05
0.01
0.01
0.05

Gonads

Red bone marrow

Colon

Lungs

Stomach

Bladder

Breasts

Liver

Esophagus

Thyroid

Skin

Bone surface

Remainder

E (mSv)

wT

Organ or Tissue

117.3

107.9

105.4

107.9

207.9

248.5

148.1

157.1

40.0

135.8

266.5

80.6

49.5

28.9

SPA

119.2

108.6

82.5

108.6

69.8

137.1

187.1

129.2

88.3

177.8

177.3

166.0

66.1

54.1

IPA

45.1

59.4

108.2

59.4

149.9

104.0

32.3

64.2

13.9

46.2

67.0

27.3

22.5

13.3

LPO

Standard Nozzle

40.4

50.3

84.0

50.3

131.9

87.9

45.9

62.1

14.4

31.6

64.2

23.3

21.3

12.9

RPO

60.5

57.9

55.5

57.9

111.4

132.0

70.0

70.6

26.9

62.7

135.0

41.5

28.8

18.6

SPA

HT (mSv)

55.1

53.5

41.1

53.5

30.4

61.5

86.5

53.4

42.6

81.3

79.0

76.5

32.9

27.0

IPA

36.5

49.5

90.8

49.5

109.4

77.5

25.3

57.6

11.5

41.7

50.9

24.3

19.6

10.7

LPO

Modified Nozzle

31.2

40.4

67.6

40.4

98.1

64.8

38.5

51.0

11.9

23.4

47.3

19.3

17.4

10.1

RPO

Values of Equivalent Dose HT, Tissue Weighting Factor wT, and Effective Dose E, from External Neutrons for the Standard Nozzle and the Nozzle with a
Modified Field-Defining Collimator and Additional Jaws
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